Table 19.23
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes[a]

SEER[b] Incidence Rates and Annual Percent Change[c] by Age at Diagnosis

All Races, Both Sexes, 2001-2006

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	34.5	150,863	-0.6	5.7	7,440	0.5	23.3	64,281	-1.2*	152.1	79,142	-0.3
1 Hodgkin Lymphoma	2.8	12,542	0.6	1.2	1,513	0.9	3.2	8,868	-0.4	4.2	2,161	3.9
2 Non-Hodgkin lymphoma	30.6	133,085	-0.5	4.5	5,886	0.4	19.4	53,591	-1.1*	141.6	73,608	-0.2
2(a) Non-Hodgkin lymphoma, B-cell	27.8	120,799	-0.3	3.1	4,035	3.7	17.3	47,935	-0.9	132.4	68,829	-0.1
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.1	5,172	4.6*	2.4	3,184	4.8*	0.6	1,536	4.0*	0.9	452	5.0
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	25.5	110,624	-0.5	0.6	810	-0.6	16.2	44,662	-1.0	125.3	65,152	-0.3
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	6.2	26,704	-1.7	-	-	-	3.1	8,720	-2.5*	34.5	17,973	-1.4
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	5.5	23,459	-2.3*	-	-	-	2.7	7,498	-3.1*	30.6	15,953	-2.0
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	124	-2.1	-	-	-	0.0	35	-	0.2	86	-
2(a) 2.1.3. Mantle-cell lymphoma	0.7	3,121	2.9*	0.0	0	-	0.4	1,187	1.7	3.7	1,934	3.7
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglubulinemia	0.6	2,685	-5.0*	-	-	-	0.3	795	-6.9*	3.6	1,888	-4.4*
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.3	1,162	-3.5	0.0	0	-	0.1	365	-8.3*	1.5	797	-1.5
2(a) 2.2.2. Waldenstrom macroglubulinemia	0.4	1,523	-6.2*	-	-	-	0.2	430	-5.6	2.1	1,091	-6.4*
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	6.9	29,917	-0.2	0.3	364	0.8	4.7	12,894	-1.2*	32.0	16,659	0.5
2(a) 2.3.1. DLBCL, NOS[d]	6.8	29,719	-0.3	0.3	356	-0.7	4.6	12,741	-1.4*	31.9	16,622	0.5
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	25	-	0.0	0	-	-	-	-	0.0	17	-
2(a) 2.3.3. Primary effusion lymphoma	0.0	31	-	0.0	0	-	0.0	23	-	-	-	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.0	142	25.4*	-	-	-	0.0	122	22.0*	-	-	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.4	1,759	-0.9	0.3	360	-2.3	0.4	984	1.8	0.8	415	-5.5*
2(a) 2.5. Marginal-zone lymphoma (MZL)	1.8	7,715	1.5	0.0	31	-	1.2	3,297	0.1	8.5	4,387	2.4*
2(a) 2.5.1. Splenic MZL	0.1	528	3.7	0.0	0	-	0.1	214	-1.1	0.6	314	6.8*
2(a) 2.5.2. Extranodal MZL, MALT[d] type	1.1	4,923	-1.0	0.0	20	-	0.8	2,205	-1.8	5.2	2,698	-0.6
2(a) 2.5.3. Nodal MZL	0.5	2,264	6.7*	-	-	-	0.3	878	5.4*	2.7	1,375	7.4*
2(a) 2.6. Follicular lymphoma	3.7	16,014	1.5	0.0	37	-	3.0	8,248	0.6	14.9	7,729	2.4*
2(a) 2.7. Hairy-cell leukemia	0.3	1,309	-2.9	0.0	0	-	0.3	838	-2.5	0.9	471	-3.5
2(a) 2.8. Plasma cell neoplasms	5.7	24,503	-1.0	-	-	-	3.2	8,879	-0.6	30.1	15,619	-1.2
2(a) 2.8.1. Plasmacytoma	0.4	1,649	0.7	-	-	-	0.3	810	-1.9	1.6	835	3.2
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	5.3	22,854	-1.1	-	-	-	2.9	8,069	-0.4	28.5	14,784	-1.4
2(a) 2.9. Heavy chain disease	0.0	18	-	0.0	0	-	-	-	-	-	-	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS[d]	1.2	5,003	1.5	0.0	41	-	0.6	1,737	-3.5*	6.2	3,225	3.9*

[a] Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.
[b] SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
[c] Annual Percent Change calculated over the time range of 2001-2006.
[d] NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.
\- Statistic not shown. Rate based on less than 16 cases for the time interval.
Trend based on less than 10 cases for at least one year within the time interval.

Table 19.23 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEER[b] Incidence Rates and Annual Percent Change[c] by Age at Diagnosis

All Races, Both Sexes, 2001-2006

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	2.0	9,008	-1.0	0.7	946	-1.4	1.7	4,674	-1.4	6.5	3,388	-0.3
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.3	1,208	-0.3	0.5	632	-2.4	0.2	492	2.5	0.2	84	1.0
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	1.7	7,690	-1.0	0.2	311	0.4	1.5	4,125	-2.0	6.3	3,254	-0.1
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.5	2,017	-3.3	0.0	42	-	0.4	1,220	-4.0	1.5	755	-2.7
2(b) 2.1.1. Mycosis fungoides	0.4	1,969	-3.2	0.0	42	-	0.4	1,204	-3.7	1.4	723	-3.0
2(b) 2.1.2. Sezary syndrome	0.0	48	-	0.0	0	-	0.0	16	-	0.1	32	-
2(b) 2.2. Peripheral T-cell lymphoma	1.1	4,967	-1.2	0.2	249	-0.4	0.9	2,526	-1.8	4.2	2,192	-0.6
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS[d]	0.4	1,754	-2.1	0.0	43	-	0.3	857	-2.8	1.6	854	-1.2
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.1	493	14.2*	-	-	-	0.1	200	17.0*	0.6	291	12.7*
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	58	-	-	-	-	0.0	33	-	0.0	18	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.3	1,202	-5.0*	0.1	159	0.0	0.2	654	-5.5*	0.7	389	-5.9
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	33	-	-	-	-	0.0	25	-	-	-	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	50	-	0.0	0	-	0.0	28	-	0.0	22	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS[d]	0.2	958	-5.3*	-	-	-	0.2	505	-6.3	0.8	441	-4.2
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	419	1.9	0.0	20	-	0.1	224	4.6	0.3	175	-0.7
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.0	177	-0.1	-	-	-	0.0	79	-3.6	0.2	92	2.5
2(b) 2.4. NK[d]/T-cell lymphoma, nasal-type/ agressive NK[d]-cell leukemia	0.1	306	7.2	-	-	-	0.1	211	7.6	0.2	81	-
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	99	-	0.0	0	-	0.0	37	-	0.1	62	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	124	6.3	0.0	0	-	0.0	52	-	0.1	72	-
2(b) 3. Non-Hodgkin lymphoma, NOS[d] , T-cell	0.0	110	-6.2	-	-	-	0.0	57	-	0.1	50	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.7	3,278	-9.2*	0.7	905	-11.3*	0.4	982	-10.1*	2.7	1,391	-7.5*
2(c) 1. Precursor lymphoblastic leukemia/ lymphoma, unknown lineage	0.3	1,518	-11.3*	0.7	892	-11.4*	0.1	366	-12.9*	0.5	260	-8.9*
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	64	-	-	-	-	0.0	18	-	0.1	44	-
2(c) 3. Non-Hodgkin lymphoma, NOS[d], unknown lineage	0.4	1,696	-7.1*	-	-	-	0.2	598	-7.9*	2.1	1,087	-6.6*
2(*) 1. Total precursor lymphoma/leukemia	1.7	7,898	0.6	3.6	4,708	0.6	0.9	2,394	0.8	1.5	796	-0.1
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	61	-	0.0	0	-	0.0	26	-	0.1	35	-
4 Lymphoid neoplasm, NOS[d]	1.2	5,175	-6.0*	0.0	41	-	0.7	1,796	-8.2*	6.3	3,338	-4.9

[a] Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.
[b] SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).
[c] Annual Percent Change calculated over the time range of 2001-2006.
[d] NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.
\- Statistic not shown. Rate based on less than 16 cases for the time interval.
Trend based on less than 10 cases for at least one year within the time interval.